UBS Group’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-350
| Closed | -$1K | – | 11877 |
|
|
2022
Q2 | $1K | Sell |
350
-1,868
| -84% | -$7.28K | ﹤0.01% | 10214 |
|
|
2022
Q1 | $9K | Sell |
2,218
-2,209
| -50% | -$9.63K | ﹤0.01% | 8640 |
|
|
2021
Q4 | $21K | Buy |
4,427
+3,727
| +532% | +$15.5K | ﹤0.01% | 7827 |
|
|
2021
Q3 | $3K | Sell |
700
-1,727
| -71% | -$6.86K | ﹤0.01% | 8920 |
|
|
2021
Q2 | $10K | Sell |
2,427
-1,399
| -37% | -$5.99K | ﹤0.01% | 8116 |
|
|
2021
Q1 | $17K | Sell |
3,826
-6,874
| -64% | -$37.9K | ﹤0.01% | 7557 |
|
|
2020
Q4 | $42K | Sell |
10,700
-2,382
| -18% | -$10.2K | ﹤0.01% | 6351 |
|
|
2020
Q3 | $53K | Sell |
13,082
-6,763
| -34% | -$28K | ﹤0.01% | 5614 |
|
|
2020
Q2 | $84K | Sell |
19,845
-6,561
| -25% | -$40K | ﹤0.01% | 5437 |
|
|
2020
Q1 | $111K | Sell |
26,406
-4,566
| -15% | -$28.8K | ﹤0.01% | 5206 |
|
|
2019
Q4 | $122K | Buy |
30,972
+18,690
| +152% | +$110K | ﹤0.01% | 5904 |
|
|
2019
Q3 | $108K | Buy |
12,282
+9,987
| +435% | +$94.4K | ﹤0.01% | 5732 |
|
|
2019
Q2 | $22K | Sell |
2,295
-1,074
| -32% | -$8.09K | ﹤0.01% | 6574 |
|
|
2019
Q1 | $22K | Sell |
3,369
-13,871
| -80% | -$90.3K | ﹤0.01% | 6258 |
|
|
2018
Q4 | $163K | Sell |
17,240
-16,461
| -49% | -$248K | ﹤0.01% | 5120 |
|
|
2018
Q3 | $678K | Buy |
33,701
+26,563
| +372% | +$694K | ﹤0.01% | 4175 |
|
|
2018
Q2 | $208K | Sell |
7,138
-90,484
| -93% | -$2.79M | ﹤0.01% | 4914 |
|
|
2018
Q1 | $2.91M | Buy |
97,622
+82,109
| +529% | +$2.65M | ﹤0.01% | 2791 |
|
|
2017
Q4 | $499K | Sell |
15,513
-3,650
| -19% | -$119K | ﹤0.01% | 4296 |
|
|
2017
Q3 | $667K | Sell |
19,163
-9,552
| -33% | -$307K | ﹤0.01% | 4006 |
|
|
2017
Q2 | $855K | Buy |
28,715
+22,684
| +376% | +$650K | ﹤0.01% | 3748 |
|
|
2017
Q1 | $180K | Sell |
6,031
-2,061
| -25% | -$52.6K | ﹤0.01% | 4710 |
|
|
2016
Q4 | $141K | Sell |
8,092
-2,395
| -23% | -$45.9K | ﹤0.01% | 5043 |
|
|
2016
Q3 | $249K | Sell |
10,487
-1,138
| -10% | -$21.4K | ﹤0.01% | 4396 |
|
|
2016
Q2 | $186K | Sell |
11,625
-839
| -7% | -$15.1K | ﹤0.01% | 4587 |
|
|
2016
Q1 | $261K | Sell |
12,464
-25,423
| -67% | -$453K | ﹤0.01% | 4307 |
|
|
2015
Q4 | $1.02M | Buy |
37,887
+28,637
| +310% | +$781K | ﹤0.01% | 3391 |
|
|
2015
Q3 | $257K | Sell |
9,250
-3,262
| -26% | -$103K | ﹤0.01% | 4439 |
|
|
2015
Q2 | $307K | Buy |
12,512
+9,221
| +280% | +$190K | ﹤0.01% | 4503 |
|
|
2015
Q1 | $61K | Sell |
3,291
-1,020
| -24% | -$20.7K | ﹤0.01% | 5870 |
|
|
2014
Q4 | $80K | Buy |
+4,311
| New | +$51.2K | ﹤0.01% | 5941 |
|
UBS Group's LJPC Position: Q3 2022 in Review
UBS Group sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 350 shares — an estimated $1K sold.
UBS Group first reported a position in LJPC in Q4 2014 and held it in 31 quarters. The position peaked at $2.91M in Q1 2018. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- UBS Group reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- UBS Group sold 350 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $1K.
- UBS Group first reported a position in La Jolla Pharmaceutical Company in Q4 2014 and held it in 31 quarters.
- UBS Group's La Jolla Pharmaceutical Company position peaked at $2.91M in Q1 2018.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.